• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Medtronic (MDT) Reasonable On Cash Flow After Its $700 Million Robotics Bet?

    Simply Wall St·10/02/2026 00:29:51
    語音播報

    Medtronic has lagged the wider market recently. The real question for anyone looking at the stock today is whether the current share price lines up with the cash flows its business is expected to generate. After a mixed stretch for the stock and fresh headlines around cardiac care and surgical robotics, the focus turns to what the company’s cash generation can support over time.

    • Over the past 3 years, Medtronic shares have returned 25.2%. This puts real weight on whether that experience still reflects what the underlying cash flows can justify from here.
    • Recent regulatory milestones in cardiac mapping software and a US$700 million surgical robotics partnership may support expectations for future cash flow. They can also shape when those cash flows arrive and how much investment is required along the way.
    • If you'd rather focus on earnings, this one's for you. See what Medtronic's 21.1x P/E says about the price.

    The issue now is whether Medtronic's current share price is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.

    If you want to test the same cash flow question you are asking of Medtronic across a broader set of opportunities in medical technology, start with 35 healthcare AI stocks.

    Is Medtronic a Bargain on Cash Flow?

    The Discounted Cash Flow (DCF) model here looks at the cash Medtronic can return to shareholders over time. On the latest twelve month view, the business generated around $6.1b of free cash flow, and analysts expect those annual cash flows to trend higher over the coming decade rather than shrink.

    Those projections rely on Medtronic continuing to produce sizeable, recurring cash generation, with only modest growth assumptions baked in rather than aggressive step changes. The DCF outcome suggests these future cash flows support an intrinsic worth meaningfully above the current share price of $86.44. Because the recent $700 million Cornerstone Robotics partnership requires upfront spending while the market opportunity builds out more gradually, that commitment helps explain why the price still lags what the DCF implies the cash flows are worth. Find out what Medtronic could be worth using our Discounted Cash Flow (DCF) estimate.

    The Medtronic Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives for Medtronic pick up where the DCF puzzle leaves off. They spell out which paths for Medtronic's growth, profitability and earnings would need to play out for the stock to end up worth materially more or less than today's price. Where a single valuation figure gives you one number, these stories unpack the future that number relies on so you can follow over time whether it is still on track.

    One of the top community narratives on Medtronic: 18% undervalued

    "The main thing that has to go right is Medtronic executing on portfolio reshaping and higher innovation spend, including the MiniMed separation..."

    Discover why this Narrative puts Medtronic at 18% undervalued.

    One more Medtronic angle that could change the story

    Cash flow and valuation only tell part of the story for Medtronic, because the people setting priorities and how they are rewarded can heavily influence what those numbers look like over time. See who runs Medtronic and how they are paid.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.